vimarsana.com

Latest Breaking News On - Oblique therapeutics - Page 1 : vimarsana.com

The Nomination Committee's proposal to the Annual General Meeting 2024

The Nomination Committee’s proposal to the Annual General Meeting 2024

United statesUppsala lanKerstin valinder strinnholmLos angelesJonas ekblomMoberg pharmaIda marie lindbergAnna ljungAnders lundmarkJens bertlingGillis cullinErnst young as company auditorsStockholm universityCompany auditorsNomination committeeUniversity of southern california

Oblique Therapeutics is delighted to announce the appointment of Christer Nordstedt M.D. PhD. as Chief Executive Officer

/PRNewswire/ Oblique Therapeutics AB (publ.), a biotechnology company focused on new antibody medicines for severe diseases with large unmet medical needs,.

Uppsala lanVastra gotalands lanKarolinska institutetMats jonassonHans peter ostlerKjell anderssonEli lillyMarie scherlundChrister nordstedtSreeshap srinivasaManagement team at oblique therapeuticsOrion corporationTeva pharmaceuticalsChief executive officerOblique therapeuticsManagement team

Oblique Therapeutics AB: Oblique Therapeutics is delighted to announce the appointment of Christer Nordstedt M.D. PhD. as Chief Executive Officer

GOTHENBURG, Sweden, Nov. 9, 2022 /PRNewswire/ Oblique Therapeutics AB (publ.), a biotechnology company focused on new antibody medicines for severe diseases with large unmet medical needs

Uppsala lanVastra gotalands lanKarolinska institutetMats jonassonHans peter ostlerKjell anderssonEli lillyMarie scherlundCecilia larssonChrister nordstedtKostenloser wertpapierhandelSreeshap srinivasaManagement team at oblique therapeuticsOrion corporationTeva pharmaceuticalsChief executive officer

Oblique Therapeutics is delighted to announce the appointment of Christer Nordstedt M.D. PhD . as Chief Executive Officer.

Gothenburg, Sweden,9 November 2022 – Oblique Therapeutics AB (publ.), a biotechnology company focused on new antibody medicines for severe diseases with large unmet medical needs, is pleased to announce the confirmation of Christer Nordstedt MD.PhD. as Chief Executive Officer (CEO). Christer Nordstedt will assume the position on 1st December 2022.

Uppsala lanKarolinska institutetMats jonassonHans peter ostlerKjell anderssonEli lillyMarie scherlundCecilia larssonChrister nordstedtSreeshap srinivasaManagement team at oblique therapeuticsOrion corporationTeva pharmaceuticalsChief executive officerOblique therapeuticsManagement team

Oblique Therapeutics is pleased to announce that the United States Patent and Trademark Office has granted a patent for its innovative AbiProt® technology

/PRNewswire/ Press release - New Patent granted Oblique Therapeutics AB today announces that key aspects of its AbiProt® technology for discovering and.

Vastra gotalands lanCecilia larssonOblique therapeuticsScience advancesOblique therapeuticAdvances publicationOblique therapeutics ab

vimarsana © 2020. All Rights Reserved.